Last updated on February 2018

Internet Surveys and Their Impact on Adherence to Brimonidine Topical Gel and QOL in Patients With Rosacea


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Rosacea
  • Age: Between 18 - 80 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Male or female subject with mild to moderate persistent erythema associated with rosacea, age greater than 18, who agrees to participate and provide written consent.
  • Have an Investigator Global Assessment of mild to moderate rosacea (IGA rating between 2 and 5 in the Investigator Global Assessment score which includes erythema in the assessment).
  • Access to a computer and the internet.

Exclusion Criteria:

  • Initiation or change in dose within 4 weeks of baseline of systemic antiinflammatory medication which may influence study outcome.
  • Use of topical therapy for rosacea within 2 weeks of baseline.
  • Use of systemic corticosteroids within 4 weeks of baseline. Presence of a concurrent medical condition or skin condition, which is determined by the investigator to potentially interfere with study outcomes or patient assessments.
  • Subjects with known allergy or sensitivity to brimonidine topical gel, 0.33% or components therein.
  • Female subjects who are not postmenopausal for at least 1 year, surgically sterile, or willing to practice effective contraception during the study. Nursing mothers, pregnant women and women planning to become pregnant while on study are to be excluded.
  • Subjects with severe cardiovascular disease or vascular insufficiency.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.